Skip to main content

Peer Review reports

From: Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

Original Submission
5 Jul 2022 Submitted Original manuscript
15 Jul 2022 Reviewed Reviewer Report - David García-azorín
24 Jul 2022 Reviewed Reviewer Report - Eiichiro Nagata
9 Aug 2022 Author responded Author comments - Roberto De Icco
Resubmission - Version 2
9 Aug 2022 Submitted Manuscript version 2
Publishing
10 Aug 2022 Editorially accepted
17 Sep 2022 Article published 10.1186/s10194-022-01480-2

You can find further information about peer review here.

Back to article page